DB
CBIO

Dmitry Balyasny’s Crescent Biopharma CBIO Stock Holding History

Dmitry Balyasny’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,500
Closed -$183K – 2896
2024
Q2 		$183K Buy
6,500
+3,201
+97% +$333K ﹤0.01% 2351
2024
Q1 		$990K Buy
+3,299
New +$985K ﹤0.01% 1797

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dmitry Balyasny's CBIO Position: Q2 2026 in Review

Dmitry Balyasny increased its Crescent Biopharma (CBIO) stake by 10% in Q2 2026, buying an estimated $2.98M and bringing the position to 1,662,917 shares worth $29.9M. The position accounts for 0.04% of the portfolio, ranked #547.

Dmitry Balyasny first reported a position in CBIO in Q1 2018 and has held it in 6 quarters since. 81 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Dmitry Balyasny held 1,662,917 shares of Crescent Biopharma worth $29.9M as of Q2 2026.
  • Dmitry Balyasny bought 152,884 Crescent Biopharma shares in Q2 2026, an estimated $2.98M.
  • Crescent Biopharma made up 0.04% of Dmitry Balyasny's portfolio in Q2 2026, its #547 holding.
  • Dmitry Balyasny first reported a position in Crescent Biopharma in Q1 2018 and has held it in 6 quarters since.
  • 81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.